Alirocumab represents a long-term opportunity to Regeneron and its partner Sanofi.
Mesoblast's acquisition of Osiris Therapeutics' MSC business makes strategic sense.
With its solid business, Baxter International is a stock to watch for investors looking for dividends.
Dyax is looking to capitalize on its unique phage display technology (companies discussed in this article include VPHM, SHPG, DYAX).
AbbVie's global alliance with Galapagos will further boost the company's financial performance.
Alnylam Pharmaceuticals is an emerging leader in a new gene-based therapy.
How Endo Health is performing in the urology devices market.
Abraxane approval for pancreatic cancer will boost Celgene's top-line.
Steris offers steady growth in multiple markets.
Teva's generic Xeloda may be a game changer for the company.
Exelixis might be a stock to watch.
Isis has many positives for investors.
Theravance is not too healthy right now.
Mannkind's Afrezza is better than Exubera, but by how much?
Gattex may seem pricey, but it will still sell.
Inovio is not for the short-sighted.
Amgen's heart drug may be revived, despite failure, all puns intended.
The fight for sofosbuvir.
A few reasons why The Medicines Company is investment grade.